Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ocumension TherapeuticsOCUTF 53 Equity-to-Asset is 0.90 as of Dec. 2025, which is at its 10-year median of 0.90. GuruFocus rates OCUTF with a GF Score™ of 53/100 and a GF Value™ of $2.32 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,413 Biotechnology companies, Ocumension Therapeutics ranks better than 83.09% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Ocumension Therapeutics Equity-to-Asset Related Terms
Ocumension Therapeutics Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCUTF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Ocumension Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Ocumension Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocumension Therapeutics (OCUTF) has a Equity-to-Asset of 0.90 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ocumension Therapeutics and its competitors. This is near median its historical median of 0.90. According to the industry distribution chart, Ocumension Therapeutics ranks #239 out of 1413 companies in the Biotechnology industry, placing it in the top 16.9%.
Is Ocumension Therapeutics' Equity-to-Asset too high?
Ocumension Therapeutics' current Equity-to-Asset of 0.90 is near median its 10-year median of 0.90. The Biotechnology industry median Equity-to-Asset is 0.68. Ocumension Therapeutics' value of 0.90 is 32.4% above this industry median. Based on the distribution chart, Ocumension Therapeutics ranks #239 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ocumension Therapeutics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #239 out of 1413 companies for Equity-to-Asset. This places Ocumension Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Ocumension Therapeutics' value of 0.90 is 32.4% above this benchmark. While the company's 10-year median is 0.90 vs. the industry median of 0.68, Ocumension Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocumension Therapeutics's current Equity-to-Asset of 0.90 is 32.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ocumension Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocumension Therapeutics's current Equity-to-Asset is 0.90, which is near median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.32, compared to a current price of $0.70 — trading 69.8% below its estimated fair value. The current Equity-to-Asset is 0.90, which is near median its 10-year median of 0.90 and 32.4% above the Biotechnology industry median of 0.68. Ocumension Therapeutics' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current Equity-to-Asset is 0.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?
Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued.
The current stock price of $0.70 is trading 69.8% below its estimated GF Value™ of $2.32.
GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.
Key valuation signals for OCUTF:
Equity-to-Asset: 0.90 (near median its 10-year median of 0.90)
GF Value™: $2.32 vs. price of $0.70 (69.8% below fair value)
Industry Position: 32.4% above the Biotechnology median (#239 of 1413)
No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
53GF Score
Get the complete analysis for OCUTF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUTF has been successfully added to your 
